ライフサイエンスコーパス: transurethral

1 Transurethral and suprapubic catheterization have both b

2 n a cross-over design to test the effects of transurethral and suprapubic catheterization.

3 s of immunization: subcutaneous, intranasal, transurethral, and oral.

4 infection provided urine samples by voided, transurethral, and/or suprapubic collection methods.

5 nosis remains cystoscopic visualization with transurethral biopsy or resection.

6 botics to improve the safety and outcomes of transurethral bladder surgery and surveillance, further

7 Trimodality therapy with transurethral bladder tumor resection and cisplatin-base

8 Pre-NAC transurethral bladder tumor specimens were sequenced for

9 l system to enhance bladder surveillance and transurethral bladder tumor, a purpose-specific robotic

10 -80 mm Hg, 20 s) air UBD was delivered via a transurethral catether and extracellular single-unit rec

11 e common in voided urine, urine collected by transurethral catheter (TUC), and urine collected by sup

12 Bladder activity was recorded via a transurethral catheter during continuous infusion (0.21

13 romic method from bladder urine collected by transurethral catheterization.

14 073 in the bladders and/or kidneys following transurethral cochallenge (P <or= 0.0139).

15 l able to compete with wild-type CFT073 in a transurethral cochallenge in mice and could colonize the

16 ils to compete with wild-type CFT073 after a transurethral cochallenge in mice and is deficient in th

17 Virulence was assessed by transurethral cochallenge of CBA mice with wild-type and

18 increased and mice were protected from acute transurethral E. coli challenge.

19 r transurethral resection of the prostate or transurethral electrovaporization of the prostate and ha

20 h formalin-killed bacteria and intranasal or transurethral immunization with purified MR/P fimbriae s

21 ive procedures such as urethral dilation and transurethral incision of the bladder neck may be improv

22 Virulence was assessed by transurethral independent challenges and cochallenges of

23 Following transurethral infection of CBA mice with a sat mutant, n

24 ign prostatic hyperplasia, transperineal and transurethral injection routes have received the most sy

25 J mice were oophorectomized, UTIs induced by transurethral inoculation of E. coli, and treated with 1

26 Transurethral inoculation of P. mirabilis(pBAC001) resul

27 noculum preparation on the day of infection, transurethral inoculation, tissue harvest and post-harve

28 itive Enterococcus faecalis, we used a mouse transurethral instillation model to address the hypothes

29 However, the transurethral laser enucleation of the prostate addresse

30 er to warrant the efficacy and safety of the transurethral laser treatment for clinical translations.

31 nt research aims to develop new non-ablative transurethral laser treatment for SUI as a minimally inv

32 nstrated the feasibility of the non-ablative transurethral laser treatment for SUI without thermal da

33 The transurethral laser treatment groups exhibited significa

34 the safety, effectiveness, and durability of transurethral microwave thermotherapy (TUMT) as a minima

35 s of mice at significantly lower levels in a transurethral model of infection.

36 e during LPP testing whether measured with a transurethral or suprapubic catheter.

37 pendectomy, hemorrhoidectomy, thyroidectomy, transurethral prostate surgery, parathyroidectomy, and c

38 n 47 men undergoing radical prostatectomy or transurethral prostatectomy at Loyola University Medical

39 rior eye, intramedullary spine, and possibly transurethral prostatectomy surgery.

40 Electrosurgical transurethral resection (TUR) of the prostate (TURP) has

41 Patients underwent transurethral resection and induction CRT to 40 Gy.

42 Transurethral resection and instillation of perioperativ

43 carcinomas of the bladder were treated with transurethral resection and intravesical bacillus Calmet

44 rficial bladder cancer is still managed with transurethral resection and perioperative instillation o

45 patients who underwent either enucleation or transurethral resection as their initial treatment.

46 Transurethral resection biopsies of the prostatic urethr

47 e bladder cancer, combined-modality therapy (transurethral resection bladder tumor [TURBT], radiation

48 of those rendered T(1) at second look after transurethral resection bladder tumor, most still requir

49 than five cases in urologists, with previous transurethral resection experience.

50 y deferred based on the clinical response to transurethral resection followed by systemic therapy.

51 Bipolar transurethral resection is a novel approach in treatment

52 nstillation of chemotherapeutic agents after transurethral resection is quickly becoming the standard

53 Transurethral resection is the cornerstone treatment for

54 Despite current treatment after transurethral resection of a bladder tumor, recurrences

55 etect urothelial bladder cancer (UBC) before transurethral resection of bladder cancer (TURBT), and (

56 y (BLC) with hexaminolevulinate (HAL) during transurethral resection of bladder cancer improves detec

57 recurrence (defined as receipt of subsequent transurethral resection of bladder tumor >3 months after

58 Transurethral resection of bladder tumor (TURBT) is the

59 s the use of intravesical chemotherapy after transurethral resection of bladder tumor before and afte

60 (BCG) induction and maintenance (I+M) after transurethral resection of bladder tumor is standard of

61 s after index diagnosis of NMIBC and initial transurethral resection of bladder tumor), progression (

62 sparing trimodal therapy (TMT) that combines transurethral resection of bladder tumor, chemotherapy f

63 After undergoing complete transurethral resection of bladder tumor, patients recei

64 Concurrently performed transurethral resection of bladder tumor-TURP seems onco

65 he number of patients requiring a procedure (transurethral resection of bladder tumors [TURBT] or off

66 ) often have recurrence or progression after transurethral resection of bladder tumour (TURBT) and su

67 Transurethral resection of bladder tumour (TURBT) is a d

68 An effective transurethral resection of bladder tumour (TURBT) is ess

69 Transurethral resection of bladder tumour (TURBT) was pe

70 Randomisation was stratified by results of transurethral resection of bladder tumour (visibly compl

71 All patients had transurethral resection of bladder tumour and twice-dail

72 ores to compare trimodality therapy (maximal transurethral resection of bladder tumour followed by co

73 h-risk non-muscle-invasive bladder cancer is transurethral resection of bladder tumour followed by in

74 Transurethral resection of bladder tumour within 12 week

75 apy or trimodality therapy (that is, maximal transurethral resection of bladder tumour, chemotherapy

76 Age (P =.78), race (P =.29), prior transurethral resection of prostate (P =.81), and treatm

77 as admitted with massive hematuria following transurethral resection of prostate for benign prostatic

78 of the procedures examined (P < .01, except transurethral resection of prostate, P = .76).

79 radiation delivered per treatment, and prior transurethral resection of prostate.

80 All patients underwent transurethral resection of the bladder (TURB) and had hi

81 biomarker test, can predict the need for 2nd transurethral resection of the bladder (TURB) better tha

82 evidence of clinical CR and received a redo transurethral resection of the bladder tumor (reTURBT).

83 Patients who received no LT, transurethral resection of the bladder tumor alone, or <

84 A transurethral resection of the bladder tumor and biopsy

85 Diagnostic cystoscopy in combination with transurethral resection of the bladder tumour are the st

86 preserving treatment (TMT) comprises maximal transurethral resection of the bladder tumour followed b

87 ons and partial obstructions respond best to transurethral resection of the ejaculatory ducts (TURED)

88 urgical retreatment (3.4%-21%) compared with transurethral resection of the prostate (5%) and holmium

89 01), prostatectomy (chi23 = 24.4; P = .001), transurethral resection of the prostate (chi23 = 51.3; P

90 rlson comorbidity score (P < .01), and prior transurethral resection of the prostate (OR, 1.65; P < .

91 state glands (> or = 60 cm3) or history of a transurethral resection of the prostate (TURP) as implan

92 Transurethral resection of the prostate (TURP) has long

93 with age, suggests that the frequent use of transurethral resection of the prostate (TURP) in recent

94 alised prostate cancer diagnosed by use of a transurethral resection of the prostate (TURP) in the UK

95 Transurethral resection of the prostate (TURP) is the st

96 Eight percent of patients underwent a transurethral resection of the prostate (TURP) within 2

97 eks after radical prostatectomy (trial 1) or transurethral resection of the prostate (TURP; trial 2)

98 ent choice over the past 10 years, replacing transurethral resection of the prostate as the standard

99 on and catheter removal policy can result in transurethral resection of the prostate being performed

100 Optimizing each stage of transurethral resection of the prostate can result in re

101 rospective study of healthy men undergoing a transurethral resection of the prostate for benign prost

102 The new technique of bipolar transurethral resection of the prostate has been studied

103 ht to the market over the past decade or so, transurethral resection of the prostate has been undergo

104 At the same time, transurethral resection of the prostate has evolved into

105 i-centre studies in effectiveness of bipolar transurethral resection of the prostate is apparent.

106 the prostate are not as effective as either transurethral resection of the prostate or transurethral

107 sion of interest in surgical alternatives to transurethral resection of the prostate over the past de

108 In total, 156 prostate tissues from transurethral resection of the prostate procedures for b

109 Transurethral resection of the prostate remains a widely

110 Transurethral resection of the prostate remains the gold

111 Transurethral resection of the prostate remains the trea

112 Like many of the surgical alternatives to transurethral resection of the prostate this procedure s

113 sks the question of whether it will relegate transurethral resection of the prostate to an operation

114 -term results suggest equivalent efficacy to transurethral resection of the prostate with improved sa

115 diagnostic tumour samples (needle biopsy or transurethral resection of the prostate).

116 biopsy, laparoscopic radical prostatectomy, transurethral resection of the prostate, and ureteroscop

117 Surgery (eg, transurethral resection of the prostate, holmium laser e

118 agement was once limited to medical therapy, transurethral resection of the prostate, or open, relati

119 benign prostatic hyperplasia continues to be transurethral resection of the prostate, which is tradit

120 etween June 2000 and July 2001 pertaining to transurethral resection of the prostate.

121 ate-specific antigen at diagnosis, and prior transurethral resection of the prostate.

122 tatic outcomes compared to classic monopolar transurethral resection of the prostate.

123 dies have compared these two techniques with transurethral resection of the prostate.

124 tic hyperplasia was the electrocautery-based transurethral resection of the prostate.

125 tioned between pharmacological treatment and transurethral resection of the prostate.

126 e deemed high surgical risks for traditional transurethral resection of the prostate.

127 ajor advances that have occurred recently in transurethral resection of the prostate.

128 t challenge to the 'gold standard' status of transurethral resection of the prostate.

129 ggest there is no significant advantage over transurethral resection of the prostate.

130 nt of superficial bladder cancer is based on transurethral resection of the tumor with perioperative

131 nonmuscle invasive bladder cancer (NMIBC) is transurethral resection of the tumors, followed by intra

132 Both transurethral resection of the ureteral orifice (pluck)

133 including tumour understaging, the number of transurethral resection procedures received by the patie

134 RECENT FINDINGS: For improving transurethral resection quality, new optical enhancement

135 Transurethral resection remains the surgical mainstay fo

136 ime, a cystoscopy of his primary tumor and a transurethral resection revealed residual muscle-invasiv

137 A total of 328 transurethral resection specimens from 232 patients were

138 itoring of irrigant absorption can eliminate transurethral resection syndrome.

139 ent have been explored, ranging from radical transurethral resection to concurrent chemoradiation.

140 is); randomization within 12 months of first transurethral resection was required.

141 Only randomized comparisons with transurethral resection will tell us if it is a worthy c

142 -sparing trimodality treatment consisting of transurethral resection with chemoradiation.

143 ients with high-risk NMIBC involves complete transurethral resection with intravesical BCG therapy.

144 ontinues to be managed predominantly through transurethral resection with perioperative instillation

145 Two to 4 weeks after complete transurethral resection, gemcitabine was administered in

146 mainstay of diagnosis remains cystoscopy and transurethral resection, with enhanced optical technique

147 ncer with particularly high recurrence after transurethral resection.

148 so observed in patient samples obtained from transurethral resection.

149 a safe, effective and durable alternative to transurethral resection.

150 f targeting of necrotic tissue from previous transurethral resections or chemotherapy are considered

151 nd based on radical prostatectomy samples or transurethral resections rather than biopsy samples.

152 lenocytes isolated from mice infected by the transurethral route robustly expressed IL-17A in respons

153 reports using transperineal, transrectal and transurethral routes with different injectables.

154 nd idealized two-dimensional CFD model after transurethral surgery (CATS-1st) was developed for post-

155 n of urine flow behavior within the PU after transurethral surgery for benign prostatic hyperplasia (

156 eter ratios of prostatic urethra (RPU) after transurethral surgery using computational fluid dynamics

157 useful for morphological repair in PU after transurethral surgery.

158 University are reviewed, including a robotic transurethral system to enhance bladder surveillance and

159 Bladder preservation with transurethral tumour resection, radiation, and chemother

160 nosis is established by urinary cytology and transurethral tumour resection.

161 With the advent of the high resolution transurethral ultrasound (TRUS) technology, there has be

162 MR imaging-controlled transurethral ultrasound therapy is feasible, safe, and

163 Transurethral ultrasound therapy was performed with the

164 Thulium laser transurethral vaporesection of the prostate (ThuVARP) is

165 Topics discussed include transurethral vaporization of the prostate, laser prosta